Sun Pharmaceutical Industries Limited

Sun Pharma Board Approves Q2 FY26 Consolidated Results and MoA Amendment for Green Energy

Sun Pharma's Board approved Q2 FY26 consolidated financial results showing increased revenue and profit, despite a standalone dip due to an exceptional item. They also proposed MoA changes for captive renewable power.

Sun Pharma Announces Special Window for Physical Share Transfer

Sun Pharma announces a special six-month window as per SEBI guidelines for re-lodgement of physical share transfer requests rejected due to deficiencies, from July 7, 2025, to January 6, 2026.

Sun Pharma to announce Q2 results on 5 Nov 2025; Earnings call scheduled

Sun Pharma will announce its Q2 results on November 5, 2025, followed by an earnings call at 6:30 PM IST on the same day to discuss the company's performance.

Sun Pharma Releases ESG Overview for FY 2024-25, Highlighting Strong Sustainability Performance

Sun Pharma released its FY 2024-25 ESG Overview, showcasing robust environmental performance, significant social impact including ₹142.4 crore CSR spend, and strong corporate governance.

NCLT approves Sun Pharma's Composite Scheme of Arrangement for subsidiary amalgamation

NCLT approved Sun Pharma's Composite Scheme of Arrangement on 7 October 2025, involving the amalgamation of five wholly-owned subsidiaries and reclassification of General Reserve.

Submission of Confirmation Certificate under SEBI (Depositories and Participants) Regulations, 2018

Sun Pharma submitted a Confirmation Certificate for the quarter ended 30 September 2025, confirming dematerialisation compliance and listing of securities as per SEBI regulations.

Sun Pharma informs about IEPF awareness campaign 'Saksham Niveshak'

Sun Pharma to meet with analysts and institutional investors in Mumbai.

US FDA classifies Sun Pharma's Halol facility as 'Official Action Indicated'

Sun Pharma Investor Presentation - August 2025

Sun Pharma to attend Motilal Oswal and Elara India Dialogue Conference in Sept 2025

Sun Pharma Reports Robust 10.1% Sales Growth, 19.2% EBITDA Surge in Q1 FY26; Advances Innovative Pipeline

Sun Pharma clarifies on news report regarding US drug pricing

Sun Pharma: Analyst/Institutional Investor Meeting Schedule

Newspaper Publication: Unaudited Financial Results for Quarter Ended 30 June 2025

Sun Pharma: Investor call audio recording

Sun Pharma's 33rd AGM: Strong FY25 Performance, ₹5.50 Dividend, and New Managing Director Appointed

Sun Pharma Q1FY26: Revenue up 10.1% YoY, Adjusted Net Profit rises 5.7%

Sun Pharma's subsidiaries to pay US$ 200 Million to settle antitrust claims

Sun Pharma's Phase 3 Studies for Psoriatic Arthritis Meet Primary Endpoint